The GP IIb/ IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation - Straub, A; Wendel, HP; Azevedo, R (Eur J Cardiothorac Surg, 2005)
et al.